Dec 12, 2013 : Bharat Book Bureau presents the new report, on 'Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics' provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all option and evaluation deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.
Chapter 4 provides a review of the leading option and evaluation deals since 2009. Deals are listed by headline value, signed by bigpharma and biobiotech, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.
In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.
Table of contents :
Chapter 1 – Introduction
Chapter 2 – Trends in option and evaluation dealmaking
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2009
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon – Ception – January 2009
2.6.2. Case study 2: Endo – Indevus – January 2009
2.6.3. The future of option to acquire deals
Chapter 3 – Overview of option and evaluation deal structure
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: BioGenerix – Neose
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec – Isis Pharmaceuticals – June 2012
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis –Prometheus
3.3.1.c. Option to finance
Case study 6: Archemix– Merck KGaA
3.3.1.d. Option to co-promote
Case study 7: Teva – OncoGenex Pharmaceuticals
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix – Nycomed
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: MGI Pharma – AkaRx
3.4.1.b. Case study 10: Abbott – Ibis Biosciences – Isis Pharmaceuticals
Chapter 4 – Leading option and evaluation deals
4.2. Top option and evaluation deals by value
4.3. Most active option and evaluation dealmakers
4.4. Big pharma option and evaluation deal activity
4.5. Big biotech option and evaluation deal activity
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: https://twitter.com/researchbook
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.